The U.S. government has released its 2026 Medicare Advantage and prescription drug plan quality ratings, offering insight into how major health insurers performed in providing care to seniors. These annual ratings, issued by the Centers for Medicare & Medicaid Services (CMS), play a key role in determining bonus payments to insurers—worth hundreds of millions or even billions of dollars—and influence plan revenues in 2027.
According to CMS data, CVS Health’s Aetna stands out with over 81% of members enrolled in top-rated plans, while UnitedHealth Group follows closely with 78%. Elevance Health improved significantly, reaching 55% of members in 4-star or higher plans, compared to 40% last year. In contrast, Humana saw only about 20%, or 1.2 million members, in highly rated plans.
Overall, 64% of all Medicare Advantage members with prescription drug coverage are enrolled in plans rated four stars or higher, according to Oppenheimer analysts. These ratings assess factors such as customer satisfaction, access to care, chronic disease management, and preventive health screenings, ensuring seniors can make informed choices when selecting coverage.
CVS Health said more than 63% of its Aetna Medicare Advantage members are in 4.5-star plans for next year. Meanwhile, UnitedHealth reported that 40% of its members are enrolled in 4.5-star or higher plans, consistent with its earlier projections. Analysts described this year’s results as largely expected, following recent company updates.
Centene’s Wellcare, led by CEO Michael Carson, also reported continued improvement, emphasizing the company’s focus on delivering high-quality, affordable healthcare and enhancing health outcomes nationwide.
As competition intensifies, star ratings continue to shape the landscape of the Medicare Advantage market, rewarding insurers that excel in quality and member satisfaction while motivating others to raise their standards.


Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 



